title: Effectiveness of combined treatment with superoxide dismutase and Reamberin during skin ischemia.
abstract: Experimental skin ischemia in rats was induced by suturing a skin fold on the back with a silk thread. Combined pretreatment with superoxide dismutase (intraperitoneally) and Reamberin (intravenously) in doses of 0.01 and 6.25 mg/kg (by succinate concentration), respectively, produced a strong protective effect on the skin. The index of cytolysis decreased by 39%. The more pronounced antinecrotic effect of combined treatment with superoxide dismutase and Reamberin compared to the effect of Reamberin alone was related to a sharp increase in the reserve capacity of the antioxidant system. After combined therapy, activity of antioxidant defense enzymes not only increased, but even exceeded the normal level. The increase in activity of endogenous superoxide dismutase under the influence of combined therapy was accompanied by suppression of superoxide anion production.
authors.affiliation: Kuban State Medical University; Krasnodar Branch, Southern Bureau of the Russian Academy of Medical Sciences, Russia.
authors.forename: V P
authors.initials: VP
authors.lastname: Galenko-Yaroshevskii
authors.forename: A V
authors.initials: AV
authors.lastname: Agadzhanova
authors.forename: N V
authors.initials: NV
authors.lastname: Lapina
authors.forename: T V
authors.initials: TV
authors.lastname: Gaivoronskaya
authors.forename: L V
authors.initials: LV
authors.lastname: Popkova
authors.forename: I V
authors.initials: IV
authors.lastname: Churilova
authors.forename: A S
authors.initials: AS
authors.lastname: Gorelashvili
authors.forename: T M
authors.initials: TM
authors.lastname: Berberashvili
authors.forename: N A
authors.initials: NA
authors.lastname: Antelava
authors.forename: G V
authors.initials: GV
authors.lastname: Sukoyan
mesh_terms: D000244:Adenosine Diphosphate / Q000032:analysis; D000255:Adenosine Triphosphate / Q000032:analysis; D000818:Animals; D000975:Antioxidants / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D007274:Injections, Intraperitoneal; D007511:Ischemia / Q000188:drug therapy* / Q000201:enzymology / Q000209:etiology / Q000473:pathology; D008297:Male; D009336:Necrosis / Q000188:drug therapy; D011897:Random Allocation; D051381:Rats; D011919:Rats, Inbred Strains; D012867:Skin / Q000098:blood supply* / Q000187:drug effects* / Q000201:enzymology; D013482:Superoxide Dismutase / Q000008:administration & dosage / Q000378:metabolism / Q000494:pharmacology*; D013481:Superoxides / Q000037:antagonists & inhibitors
chemical_list: D000975:Antioxidants; D013481:Superoxides; D000244:Adenosine Diphosphate; D000255:Adenosine Triphosphate; D013482:Superoxide Dismutase